Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?

PET Clin. 2020 Jan;15(1):35-43. doi: 10.1016/j.cpet.2019.08.008. Epub 2019 Oct 29.


Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.

Keywords: Cancer; Checkpoint inhibitors; Immunotherapy; Molecular imaging; PD-1; PD-L1; immunoPET.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use
  • B7-H1 Antigen / antagonists & inhibitors*
  • B7-H1 Antigen / metabolism
  • Biomarkers, Tumor / metabolism
  • Clinical Trials as Topic
  • Forecasting
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / diagnostic imaging
  • Neoplasms / therapy*
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography / methods
  • Tomography, Emission-Computed, Single-Photon / methods
  • Tumor Microenvironment


  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human